HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) wi

CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two indep

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentat

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive resu

-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster

-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster

UBS analyst David Dai maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the pric

Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight

Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and

Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Conse

Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.18) per share which beat the ana

HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial resul

Celldex is positioned as a platform immunology company, leveraging barzolvolimab's mast-cell depleti

The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While

Barclays analyst Etzer Darout upgrades Celldex Therapeutics (NASDAQ:CLDX) from Underweight to Ove

Celldex Therapeutics (NASDAQ: CLDX) executives used an appearance at H.C. Wainwright's annual Inflam

HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that managem

SG Americas Securities LLC grew its position in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 143.2%

HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Comp

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Comp

Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announce

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Comp

Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials

- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of li

Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) has earned an average recommendation of

Goldman Sachs analyst Richard Law maintains Celldex Therapeutics (NASDAQ:CLDX) with a Neutral and

- Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm

Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials

- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, su

Stifel analyst Alex Thompson reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises

Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.22) per share which missed the a

HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial resu

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treat

HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completio

Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew m

Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent